Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Lilly shares were down 8% in Thursday premarket trading to $826.57. In an interview Thursday morning, Lilly CEO David Ricks ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Eli Lilly (LLY) will report Q1 results on Thursday. Analysts expect in line results with focus on tirizepatide and obesity franchise.

Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer (PFE) has been the focus of ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

SALT LAKE CITY — Goldman Sachs announced applications are open in Utah for its $100-million investment initiative to provide education and loans to small businesses in rural communities.